HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ying Xie Selected Research

Chronic Disease (Chronic Diseases)

4/2021Urinary Proteomic Characteristics of Hyperuricemia and Their Possible Links with the Occurrence of Its Concomitant Diseases.
1/2021The prevalence of multimorbidity in primary care: a comparison of two definitions of multimorbidity with two different lists of chronic conditions in Singapore.
12/2020Comparing the prevalence of multimorbidity using different operational definitions in primary care in Singapore based on a cross-sectional study using retrospective, large administrative data.
1/2020Compositional characterization of Pyrus ussuriensis Maxim and their antioxidant activities and induction of apoptosis in Bel-7402 cell.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ying Xie Research Topics

Disease

134Neoplasms (Cancer)
05/2024 - 12/2009
31Breast Neoplasms (Breast Cancer)
03/2024 - 11/2014
24Inflammation (Inflammations)
11/2023 - 05/2008
20Neoplasm Metastasis (Metastasis)
02/2024 - 12/2009
14Rheumatoid Arthritis
12/2023 - 12/2016
13Multiple Myeloma
04/2024 - 01/2018
13Hypoxia (Hypoxemia)
10/2023 - 01/2017
13Fibrosis (Cirrhosis)
05/2023 - 08/2014
13Lung Neoplasms (Lung Cancer)
12/2022 - 02/2010
12Hepatocellular Carcinoma (Hepatoma)
05/2024 - 10/2014
10Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2023 - 02/2010
10Carcinogenesis
01/2022 - 04/2014
10Nasopharyngeal Carcinoma
01/2018 - 06/2006
9Atherosclerosis
01/2023 - 04/2008
9Colitis
01/2022 - 09/2010
9Liver Diseases (Liver Disease)
01/2020 - 05/2013
8Necrosis
12/2021 - 11/2003
7Colorectal Neoplasms (Colorectal Cancer)
04/2024 - 11/2014
7Infections
04/2024 - 02/2010
7Triple Negative Breast Neoplasms
03/2024 - 01/2017
7Non-alcoholic Fatty Liver Disease
04/2023 - 01/2014
7Arthritis (Polyarthritis)
01/2023 - 03/2007
6Disease Progression
10/2023 - 11/2019
6COVID-19
05/2023 - 01/2020
6Type 2 Diabetes Mellitus (MODY)
11/2022 - 08/2009
6Crohn Disease (Crohn's Disease)
01/2022 - 09/2010
6Pancreatic Neoplasms (Pancreatic Cancer)
12/2021 - 01/2016
6Ovarian Neoplasms (Ovarian Cancer)
01/2019 - 01/2018
5Obesity
01/2024 - 01/2020
5Insulin Resistance
01/2024 - 01/2014
5Edema (Dropsy)
11/2023 - 10/2017
5Body Weight (Weight, Body)
03/2023 - 10/2016
5Hemorrhage
01/2023 - 01/2009
5Heart Failure
01/2023 - 04/2018
5Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2022 - 01/2019
5Pain (Aches)
02/2021 - 09/2016
4Acute Kidney Injury (Acute Renal Failure)
04/2024 - 01/2018
4Virus Diseases (Viral Diseases)
01/2023 - 01/2013
4Wounds and Injuries (Trauma)
03/2022 - 01/2014
4Ulcerative Colitis
01/2022 - 08/2019
4Chronic Disease (Chronic Diseases)
04/2021 - 01/2020
4Gouty Arthritis
02/2021 - 09/2016
3Fatty Liver
05/2024 - 01/2014

Drug/Important Bio-Agent (IBA)

29Proteins (Proteins, Gene)FDA Link
09/2023 - 08/2014
20Biomarkers (Surrogate Marker)IBA
01/2023 - 11/2003
18MicroRNAs (MicroRNA)IBA
04/2024 - 02/2010
12LipidsIBA
04/2024 - 04/2008
11EnzymesIBA
10/2023 - 11/2014
11Small Interfering RNA (siRNA)IBA
12/2022 - 09/2014
10CytokinesIBA
03/2023 - 01/2018
9Messenger RNA (mRNA)IBA
01/2023 - 05/2011
8Reactive Oxygen Species (Oxygen Radicals)IBA
05/2024 - 01/2017
8Transcription Factors (Transcription Factor)IBA
01/2024 - 11/2014
8Glucose (Dextrose)FDA LinkGeneric
04/2023 - 01/2018
8Therapeutic UsesIBA
01/2023 - 06/2011
8Doxorubicin (Adriamycin)FDA LinkGeneric
08/2022 - 01/2017
7RNA (Ribonucleic Acid)IBA
01/2023 - 01/2019
7Peptides (Polypeptides)IBA
01/2023 - 02/2014
7LigandsIBA
07/2022 - 01/2012
7Interleukin-6 (Interleukin 6)IBA
01/2022 - 10/2016
7Silybin (Lagosa)IBA
01/2021 - 01/2017
6AlkaloidsIBA
12/2023 - 05/2008
6Liposomes (Liposome)IBA
10/2023 - 01/2015
6AcidsIBA
08/2023 - 01/2015
6CollagenIBA
03/2023 - 10/2017
6Chemokine ReceptorsIBA
12/2021 - 01/2016
6DNA (Deoxyribonucleic Acid)IBA
10/2021 - 06/2006
5Blood Glucose (Blood Sugar)IBA
01/2024 - 01/2021
5ProdrugsIBA
07/2023 - 01/2017
5Long Noncoding RNAIBA
01/2023 - 08/2019
5Proteasome InhibitorsIBA
01/2023 - 01/2020
5CholesterolIBA
01/2023 - 01/2017
5Paclitaxel (Taxol)FDA LinkGeneric
12/2022 - 04/2019
5Cisplatin (Platino)FDA LinkGeneric
02/2022 - 01/2018
5AntioxidantsIBA
06/2021 - 01/2018
5Phenobarbital (Luminal)FDA Link
10/2019 - 11/2014
5Chloroquine (Aralen)FDA LinkGeneric
01/2018 - 03/2016
4Indicators and Reagents (Reagents)IBA
04/2024 - 01/2011
4Methotrexate (Mexate)FDA LinkGeneric
12/2023 - 01/2019
4Estrogen ReceptorsIBA
01/2023 - 01/2016
41-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2023 - 12/2009
4LipopolysaccharidesIBA
12/2022 - 05/2011
4nobiletinIBA
08/2022 - 12/2015
4ChemokinesIBA
01/2021 - 01/2014
4AntigensIBA
10/2020 - 09/2008
4Dextrans (Dextran)FDA Link
01/2020 - 07/2017
4sodium sulfate (sodium bisulfate)FDA LinkGeneric
01/2020 - 07/2017
4oxidized low density lipoproteinIBA
11/2019 - 01/2015
4SilymarinIBA
10/2019 - 05/2013
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 12/2009
46-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
01/2018 - 01/2015
4Brain-Derived Neurotrophic Factor (BDNF)IBA
04/2017 - 06/2014

Therapy/Procedure

60Therapeutics
05/2024 - 12/2010
20Drug Therapy (Chemotherapy)
03/2024 - 12/2015
18Chinese Traditional Medicine (Traditional Chinese Medicine)
04/2024 - 05/2015
12Immunotherapy
04/2024 - 03/2010
5Photochemotherapy (Photodynamic Therapy)
01/2023 - 12/2009
5Radiotherapy
01/2022 - 06/2012
4Oral Administration
01/2024 - 03/2007
4Percutaneous Coronary Intervention
09/2022 - 01/2009